醫療產業的DX (數位轉型) 和新技術 (2020年版)
Digital Transformation and Emerging Technology in the Healthcare Industry - 2020 Edition
|出版日期||內容資訊||英文 73 Pages
|醫療產業的DX (數位轉型) 和新技術 (2020年版) Digital Transformation and Emerging Technology in the Healthcare Industry - 2020 Edition|
|出版日期: 2020年10月31日||內容資訊: 英文 73 Pages||
全球製藥行業面臨管理問題（利潤率下降，成本壓力，管道產品補充等），許多監管挑戰以及面臨當今的新型冠狀病毒感染疾病 (COVID-19) 的金融動盪。為了克服這種情況，即使在製藥行業中也不可避免地要引入DX（數位轉型）。
The pharmaceutical industry is undergoing constant changes resulting from declining profit margins, cost pressure, and the necessity to replenish pipelines and maximize peak sales, while at the same time meeting stringent regulatory and legislative requirements. Although digital transformation was seen as one of the ways to ease these pressures, the COVID-19 crisis is making digital transformation even more pressing. As the pandemic takes its toll on businesses, pharma is also forced to adopt to an ever-changing environment defined by supply chain disruptions, delays in clinical trials, evolving regulatory requirements, intense competition, lockdowns, and social distancing norms.
Technology is no longer viewed as enabling business, but as driving it. It is fundamental to number of operations and is changing the value chain in a disruptive way. As the new technologies are being adopted by the healthcare industry it is important to understand what opportunities and challenges they bring.
A total of 194 GlobalData Pharma clients and prospects participated in the 10-minute survey, which was fielded from September 17, 2020 to October 6, 2020.
The respondents who did not have a digital transformation strategy in place and were not working towards one were excluded from data analysis in this report, bringing the final respondent count to 156.
Components of the report include -